Vulnerable plaques are prone to rupture and can cause acute coronary syndromes. The goals of these 3 collaborative projects are to identify the mechanisms related to the formation and stabilization of vulnerable plaques and to develop non-invasive methods for their detection and characterization. Project 1 focuses on the protective effects of HDL.
In aims 1 and 2, mouse models of human atherosclerosis will be used to identify the mechanisms by which HDL can retard the progression of plaque formation (aim 1) or promote the regression and stabilization of established lesions (aim 2). To elevate HDL levels after lesions are established, strategies based on transplant surgery and gene transfer will be used.
In aim 3, magnetic resonance imaging (MRI), capable of noninvasively characterizing advanced lesions in mouse abdominal aorta, will be further developed to serially assess lesion changes in mice (from Projects 1 and 2) during plaque progression, regression, or stabilization. Project 2 focuses on the central role of the macrophage in plaque formation and de-stabilization.
Aim 1 will examine the potential of dexamethasone (Dex) to affect plaque progression/regression and the expression of monocyte chemoattractant protein-1 (MCP-1; a pro- atherogenic product of macrophages) in induced mutant mouse models treated by diet or vessel injury.
Aim 2 will focus on the molecular regulation of Dex-induced instability of MCP-1 mRNA.
In aim 3, a novel mouse model will be developed and studied in which macrophages can be specifically ablated at selected time points to determine their importance in plaque progression, regression, and, importantly, rupture. Project 3 will characterize vulnerable plaques by MRI in humans.
In aim 1, asymptomatic patients with dyslipidemia and patients with stroke will be screened for plaques in the thoracic aorta and carotid arteries. Plasma lipid levels will be modified by therapy with a statin or statin plus niacin (to raise HDL) and changes in plaque size and composition will be followed serially by MRI.
In aim 2, a porcine model of human coronary artery disease will be used to develop MRI techniques to detect and characterize coronary plaques, then these techniques will be applied to humans. Overall, the 3 projects represent highly interactive efforts of experienced investigators who will develop new approaches to the vulnerable plaque using molecular biology, animal models, clinical investigation, and MRI.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL061814-02
Application #
6078052
Study Section
Special Emphasis Panel (ZHL1-CSR-B (S1))
Project Start
1998-09-30
Project End
2002-09-29
Budget Start
1999-09-30
Budget End
2000-09-29
Support Year
2
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
114400633
City
New York
State
NY
Country
United States
Zip Code
10029
Hewing, Bernd; Parathath, Saj; Barrett, Tessa et al. (2014) Effects of native and myeloperoxidase-modified apolipoprotein a-I on reverse cholesterol transport and atherosclerosis in mice. Arterioscler Thromb Vasc Biol 34:779-89
Barazza, Alessandra; Blachford, Courtney; Even-Or, Orli et al. (2013) The complex fate in plasma of gadolinium incorporated into high-density lipoproteins used for magnetic imaging of atherosclerotic plaques. Bioconjug Chem 24:1039-48
Rong, James X; Blachford, Courtney; Feig, Jonathan E et al. (2013) ACAT inhibition reduces the progression of preexisting, advanced atherosclerotic mouse lesions without plaque or systemic toxicity. Arterioscler Thromb Vasc Biol 33:4-12
Skajaa, Torjus; Cormode, David P; Falk, Erling et al. (2010) High-density lipoprotein-based contrast agents for multimodal imaging of atherosclerosis. Arterioscler Thromb Vasc Biol 30:169-76
Cormode, David P; Roessl, Ewald; Thran, Axel et al. (2010) Atherosclerotic plaque composition: analysis with multicolor CT and targeted gold nanoparticles. Radiology 256:774-82
Feig, Jonathan E; Quick, John S; Fisher, Edward A (2009) The role of a murine transplantation model of atherosclerosis regression in drug discovery. Curr Opin Investig Drugs 10:232-8
Williams, Kevin Jon; Feig, Jonathan E; Fisher, Edward A (2008) Rapid regression of atherosclerosis: insights from the clinical and experimental literature. Nat Clin Pract Cardiovasc Med 5:91-102
Williams, Kevin Jon; Feig, Jonathan E; Fisher, Edward A (2007) Cellular and molecular mechanisms for rapid regression of atherosclerosis: from bench top to potentially achievable clinical goal. Curr Opin Lipidol 18:443-50
Doherty, Terence M; Fisher, Edward A; Arditi, Moshe (2006) TLR signaling and trapped vascular dendritic cells in the development of atherosclerosis. Trends Immunol 27:222-7
Trogan, Eugene; Feig, Jonathan E; Dogan, Snjezana et al. (2006) Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci U S A 103:3781-6

Showing the most recent 10 out of 42 publications